Technical Analysis for VVUS - VIVUS, Inc.

Grade Last Price % Change Price Change
grade F 2.72 0.74% 0.02
VVUS closed up 0.74 percent on Friday, January 17, 2020, on 15 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical VVUS trend table...

Date Alert Name Type % Chg
Spinning Top Other 0.74%
Narrow Range Bar Range Contraction 0.74%
Inside Day Range Contraction -0.55%
20 DMA Support Bullish 0.74%
Down 3 Days in a Row Weakness 0.74%
Down 4 Days in a Row Weakness 0.74%
50 DMA Resistance Bearish -1.09%
Spinning Top Other -1.09%
Weak + Overbought Other -1.09%
Overbought Stochastic Strength -1.09%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Medicine Chemistry Health Biopharmaceutical Diabetes Obesity Diabetes Mellitus Hypertension Psychiatric Diagnosis Sleep Disorders Obstructive Sleep Apnea Sleep Apnea Erectile Dysfunction Treatment Of Obesity Chronic Weight Management Female Sexual Dysfunction High Cholesterol

Is VVUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.78
52 Week Low 2.49
Average Volume 59,037
200-Day Moving Average 3.48
50-Day Moving Average 2.75
20-Day Moving Average 2.68
10-Day Moving Average 2.75
Average True Range 0.10
ADX 10.91
+DI 19.19
-DI 19.30
Chandelier Exit (Long, 3 ATRs ) 2.56
Chandelier Exit (Short, 3 ATRs ) 2.78
Upper Bollinger Band 2.87
Lower Bollinger Band 2.48
Percent B (%b) 0.61
BandWidth 14.53
MACD Line -0.02
MACD Signal Line -0.03
MACD Histogram 0.0157
Fundamentals Value
Market Cap 287.82 Million
Num Shares 106 Million
EPS 0.31
Price-to-Earnings (P/E) Ratio 8.77
Price-to-Sales 0.55
Price-to-Book 13.45
PEG Ratio -2.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.81
Resistance 3 (R3) 2.81 2.78 2.79
Resistance 2 (R2) 2.78 2.76 2.78 2.79
Resistance 1 (R1) 2.75 2.74 2.76 2.75 2.78
Pivot Point 2.72 2.72 2.73 2.72 2.72
Support 1 (S1) 2.69 2.70 2.71 2.69 2.66
Support 2 (S2) 2.66 2.68 2.66 2.65
Support 3 (S3) 2.63 2.66 2.65
Support 4 (S4) 2.63